{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-23-000117","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.557230+00:00","generated_at":"2026-06-11T05:37:19.796534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medtronic Q1 revenue $7.7B (+6% organic); raises FY24 guidance","bullets":["Revenue $7.70B, +4.5% reported, +6.0% organic; GAAP EPS $0.59 (-16%), non-GAAP EPS $1.20 (+6%).","FY24 organic revenue growth guidance raised to 4.5% (from 4.0-4.5%); non-GAAP EPS guidance raised to $5.08-$5.16 (from $5.00-$5.10).","All four segments delivered 6% organic growth: Cardiovascular +6.2%, Neuroscience +5.6%, Medical Surgical +6.1%, Diabetes +6.3%.","U.S. launches commenced for MiniMed 780G system and Micra AV2/VR2 leadless pacemakers.","Management cites broad strength and improved fundamentals; raises guidance based on Q1 outperformance."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-23-000117","json":"https://secwatch.observer/filing/0001613103-23-000117.json","markdown":"https://secwatch.observer/filing/0001613103-23-000117.md","text":"https://secwatch.observer/filing/0001613103-23-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000117/0001613103-23-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000117/mdt-20230822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:37:19.796534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"664cf7a318ecc8f2440e65c071379a5dd0f1aefd","claim":"Medtronic plc reported first quarter of fiscal year 2024 (FY24), which ended July 28, 2023 results: revenue $7.702 billion, net income $791 million, EPS $0.59. Guidance raised.","evidence_excerpt":"Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2024 (FY24), which ended July 28, 2023. Key Highlights • Revenue of $7.7 billion increased 4.5% as reported and 6.0% organic • GAAP diluted earnings per share (EPS) of $0.59 decreased 16%; non-GAAP diluted EPS of $1.20 increased 6% • Company increases FY24 organic revenue growth and EPS guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000117/0001613103-23-000117-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal year 2024 (FY24), which ended July 28, 2023"},{"label":"Revenue","value":"$7.702 billion"},{"label":"Net income","value":"$791 million"},{"label":"EPS","value":"$0.59"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}